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The common genetic loci that independently influence the risk of
type 1 diabetes have largely been determined. Their interactions
with age-at-diagnosis of type 1 diabetes, sex, or the major
susceptibility locus, HLA class II, remain mostly unexplored. A
large collection of more than 14,866 type 1 diabetes samples
(6,750 British diabetic individuals and 8,116 affected family
samples of European descent) were genotyped at 38 confirmed
type 1 diabetes-associated non-HLA regions and used to test for
interaction of association with age-at-diagnosis, sex, and HLA
class II genotypes using regression models. The alleles that
confer susceptibility to type 1 diabetes at interleukin-2 (IL-2),
IL2/4q27 (rs2069763) and renalase, FAD-dependent amine oxi-
dase (RNLS)/10q23.31 (rs10509540), were associated with a lower
age-at-diagnosis (P = 4.6 3 1026 and 2.5 3 1025, respectively).
For both loci, individuals carrying the susceptible homozygous
genotype were, on average, 7.2 months younger at diagnosis than
those carrying the protective homozygous genotypes. In addition
to protein tyrosine phosphatase nonreceptor type 22 (PTPN22),
evidence of statistical interaction between HLA class II genotypes
and rs3087243 at cytotoxic T-lymphocyte antigen 4 (CTLA4)/
2q33.2 was obtained (P = 7.90 3 1025). No evidence of differen-
tial risk by sex was obtained at any loci (P $ 0.01). Statistical
interaction effects can be detected in type 1 diabetes although
they provide a relatively small contribution to our understanding
of the familial clustering of the disease. Diabetes 61:3012–
3017, 2012
K
nowledge of the genetic architecture of type 1
diabetes has increased recently owing to large-
scale genome-wide association (GWA) studies
(1–3). Estimates of the contributions of the HLA
region and numerous non-HLA loci across the genome now
account for a sizeable proportion of familial clustering of
the disorder (4–6). However, there remains substantial fa-
milial clustering that is not explained by the known loci
(likely to be in excess of 40%) (4–6). Interactions between
risk loci beyond that of a multiplicative model on the odds
ratio (OR) scale (or additive on the log odds scale (7)) could
account for some of the “missing heritability.” In addition, the
existence of differential effects according to age-at-diagnosis
and sex remains relatively unexplored.
The HLA region on chromosome 6p21 is the major source
of familial clustering in type 1 diabetes (4). HLA-DRB1 and
HLA-DQB1 are associated with ORs in excess of 10 for
susceptible genotypes (or less than 0.1 for protective geno-
types) (8). The risk genotype HLA-DRB1*03/HLA-DRB1*04-
HLA-DQB1*0302 (referred to as DR3/DR4-DQ302) with
greatest effect has been shown to have the highest
frequency in the individuals with youngest onset (9). An
age-at-diagnosis interaction has also been reported for
HLA-DRB1*04 (10) and the HLA class I alleles HLA-A*24
and HLA-B*39 (11,12).
In contrast, reports of age-at-diagnosis interaction effects
at non-HLA loci are contradictory, with positive reports
largely confined to studies involving small sample sets (3,13–
15). Similarly, reports of gene–gene interaction of type 1
diabetes–associated regions are also mainly conflicting (16–
19), we presume due to inadequate sample sizes, with most
positive reports likely to be false because the false-discovery
rate would be high in these underpowered studies. The only
convincing gene–gene interaction reported, is between
a major non-HLA locus, protein tyrosine phosphatase non-
receptor type 22 (PTPN22) and DR3/DR4-DQ302 genotypes
(20–23).
The incidence of childhood type 1 diabetes is similar in
males and females, unlike other autoimmune diseases
such as Graves disease, celiac disease, or multiple sclerosis.
Despite similar frequencies of childhood type 1 diabetes by
sex, there have been reports of genetic risk factors differing
between males and females (22,24).
Given that most studies of gene–gene interaction, age-at-
diagnosis effects, and sex effects on type 1 diabetes risk have
not been addressed in sufficiently well-powered studies,
the Type 1 Diabetes Genetics Consortium (T1DGC) has
collected more than 16,000 type 1 diabetes–affected samples
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and tested them for interaction effects with sex and age-
at-diagnosis at 38 non-HLA type 1 diabetes–associated
regions (Supplementary Table 2). Gene–gene interaction
was also tested between HLA class II and the 38 non-HLA
loci. With this very large sample set, the study had at least
80% power to detect effects as small as an interaction OR =
1.12 for sex and 1.19 for interactions with age-at-diagnosis
or HLA. These calculations assume a multiplicative (log
additive) effects model, an OR = 1.15 for association with
type 1 diabetes for the test locus and a minor allele fre-
quency of 0.2 and a = 0.0004. In contrast, with 5,000
samples, which is twice as large as any other study testing
for interaction effects in type 1 diabetes published to date,
the study would only be powered at 80% to detect in-
teraction effects larger than an OR = 1.3 with sex (with the
same assumptions as above). For age-at-diagnosis in-
teraction, an OR $ 1.37 could be detected; for HLA in-
teraction, an OR $ 1.38 could be detected (Supplementary
Figs. 1–6).
RESEARCH DESIGN AND METHODS
Subjects. All subjects were of white European ancestry and are described in
Table 1.
Single nucleotide polymorphism genotyping. Samples were genotyped
using TaqMan assays or, where available, existing genotype data from twoGWA
studies in a subset of the British individuals was used and has been described
elsewhere (1,2). All TaqMan genotyping was performed at the University of
Cambridge, blinded to disease status, and double-scored. In this sample set,
18% of British case genotypes were common to both TaqMan and single nu-
cleotide polymorphism (SNP) chip platforms. Concordance across genotypes
was excellent (99.63%), and therefore, no further samples were double-
genotyped. A total of 26.9% of genotypes in the British samples were from SNP
chips that used a SNP call rate of 0.95, minor allele frequency of 0.01, and
Hardy-Weinberg equilibrium cutoff of P , 5.7 3 1028. All SNPs tested in the
current study were in Hardy-Weinberg equilibrium in unaffected parents (P .
0.01) and controls (P $ 0.01).
Statistical methods. Cases and affected offspring were both used to test for
age-at-diagnosis effects in a regression model, with age-at-diagnosis as the
outcome variable and genotype as the predictor, stratified by geographic region
(cases) and collection (family samples). Robust variance estimates were used
to account for nonindependence within families. Sex effects on genotype
associations were tested in a similar manner using a logistic regression model
with sex as the outcome variable. To test for differences in age-at-diagnosis by
sex, age-at-diagnosis was used as the predictor and sex was a dependent
variable in a logistic regression model. A genetic risk score was generated from
the predictors of a logistic regression model, with disease status as the outcome
variable and age-at-diagnosis associated loci (at P , 0.05, including DR3/DR4-
DQB1*0302) as independent variables in the case–control data. We defined
(statistical gene–gene) interaction as a deviation from a multiplicative in-
teraction of the two test loci on the OR scale, equivalent to an additive model
on the log odds scale (7).
To maximize power, interaction between the type 1 diabetes–associated
SNPs and the HLA SNPs was tested in cases and affected offspring, which
requires the SNPs to be conditionally independent in the general population
(25). Two SNPs, rs2187668 and rs7454108, were used to tag the HLA-DRB1*03
(DR3) and HLA-DRB1*04 (not including HLA-DRB1*0403 and 0407; DR4) class
II alleles (linkage disequilibrium r2 = 0.99 and 0.77 in cases, respectively). SNP
coding was corrected to those of the classical genotypes where HLA-DRB1
classical genotypes were available (13,425 cases and affected offspring). Lo-
gistic regression was used to test for nonmultiplicative interaction, with the
DR3/DR4-DQ302 genotype as the binary outcome variable, SNP genotype as
the dependent variable, and geographic region or collection (for families and
Danish cases) included as strata. Robust variance estimates, which relax the
assumption of independent observations, were used for all gene–gene in-
teraction tests to allow for nonindependence within families. SNP genotype
was also regressed on class II genotypes using a linear regression model ad-
justed for geographic region or collection. Joint effects of SNP and HLA
genotype were estimated using the method of Umbach and Weinberg (25) for
case–control data, as detailed in Smyth et al. (20), and the method of Cordell
et al. (26) for family data. Combined effects from family and case–control data
were computed by the sum of effects (the vector of coefficients from the re-
gression models), weighted by their variances, and divided by the sum of the
weights (inverse of the variances). Quanto (http://hydra.usc.edu/GxE/) was
used for power calculations. All other statistical analyses were performed in
Stata (www.stata.com) or R (www.r-project.org) software. P , 0.0004 was
considered significant, which equates to a Bonferroni correction for the
number of loci and interactions tested.
RESULTS
Two of the 38 susceptibility loci tested were associated
with age-at-diagnosis, rs2069763 at interleukin 2 (IL2)/
4q27 (P = 4.6 3 1026) and rs10509540 at renalase, FAD-
dependent amine oxidase (RNLS)/10q23.31 (P = 2.5 3 1025;
Supplementary Table 2). Consistent with a true biologically
plausible age-at-diagnosis effect, the protective allele was
more frequent with increasing age-at-diagnosis and the
TABLE 1












British* Great Britain 8,512 (52) 7.7 (16)
Danish Denmark 1,789 (51) 9.0 (18)†
Family samples
T1DGC Europe 1,180 2,444 (51) 12.5 (52)
T1DGC Asia-Pacific 277 571 (48) 10.9 (40)
T1DGC North America 1,017 2,135 (54) 10.0 (49)
T1DGC U.K. 154 336 (46) 8.3 (33)
Diabetes UK, Warren Great Britain 470 997 (53) 11.6 (50)
Yorkshire Great Britain 80 84 (51) 9.6 (15)
Belfast U.K. 262 283 (54) 7.3 (16)
Romanian Romania 423 446 (48) 12.5 (52)
Finnish Finland 1,230 1,418 (54) 9.0 (46)
HBDI U.S. 335 706 (52) 10.3 (51)
Most cases were diagnosed with type 1 diabetes in childhood; however, across the family collections, 1,216 were aged older than 18 at
diagnosis, and 196 of those were aged older than 30 years at diagnosis. Minor allele frequencies for each SNP within each cohort for type 1
diabetes samples are reported in Supplementary Table 1. HBDI, Human Biological Data Interchange. *The UK Genetic Resource Investigating
Diabetes childhood cases (www.childhood-diabetes.org.uk/grid.shtml). †Age-at-diagnosis for individual Danish cases was unknown, so in-
formation applies to the whole cohort.
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mean age-at-diagnosis increased with the number of
protective alleles (Table 2). At rs2069763 (IL2/4q27) the
major allele G confers protection from type 1 diabetes
(www.t1dbase.org). The average age-at-diagnosis for G/G
homozygotes was 9.3 years compared with 8.7 years for
T/T homozygotes (7.2 months later). Furthermore, the fre-
quency of the G allele was 2.8% higher in the upper quartile
of the age-at-diagnosis distribution (64.1%) compared with
the lower quartile (61.3%; Table 2). Similarly, for rs10509540
in RNLS/10q23.31, the minor allele C confers protection
from type 1 diabetes (1), with the average age-at-diagnosis
7.2 months later for C/C homozygotes (9.5 years) compared
with T/T homozygotes (8.9 years). The frequency of the C
allele was also 2.3% higher in the upper quartile (24.2%)
compared with the lower quartile (21.9%) of the age-at-
diagnosis distribution (Table 2). The age-at-diagnosis effects
at RNLS and IL2 were independent of each other (and also
of the known DR3/DR4-DQ302 age-at-diagnosis effect), with
the average age-at-diagnosis of individuals homozygous for
the susceptible T/T genotype at both loci reduced to 8.4
years.
No convincing association with sex was obtained at any
of the 38 loci (minimum P $ 0.01; Supplementary Table 2).
However, there was suggestive evidence that females had
a lower mean age-at-diagnosis (8.9 years) than males (9.2
years, P = 7.29 3 1024), consistent with the literature for
adult-onset autoimmune type 1 diabetes (10).
HLA-SNP interaction results. HLA was modeled using
the SNPs, rs2187668 and rs7454108, to capture the DR3
and DR4 (not HLA-DRB1*0403 or HLA-DRB1*0407) haplo-
types, respectively, in a maximum of 18,548 type 1 diabetes
individuals and affected offspring (the minimum number
of samples used was 16,336, for rs689 at the insulin [INS]
gene; Supplementary Table 2). We obtained evidence of
a statistical interaction (deviation from a multiplicative in-
teraction on the OR scale) between the DR3/DR4-DQB1*0302
genotype and the PTPN22 SNP, rs2476601 (P = 7.82 3 1026).
We confirm previous reports (20–23) that the effect of the
PTPN22 SNP was to increase susceptibility in those who
are DR3/DR4-DQ302–negative compared with those who
are DR3/DR4-DQ302–positive. The OR at rs2476601 for
the T allele was 1.70 in the DR3/4-DQ302–positive group
and 1.98 in the DR3/4-DQ302–negative group (Table 3).
Importantly, DR3/DR4-DQ302 individuals remain signifi-
cantly more susceptible than the non–DR3/DR4-DQ302
individuals, regardless of PTPN22 genotype (Table 3).
Some evidence of deviation from multiplicative interaction
on the OR scale (although not at P # 4 3 1024) was also
obtained between the 17q12 region, containing the candi-
date genes gasdermin B (GSDMB) and ORM1-like 3 (oro-
somucoid 1-like 3, ORMDL3) (rs2290400 G.A) and with
the DR3/DR4-DQ302 genotype (P = 6.24 3 1024). The in-
teraction between HLA and rs2290400 manifested as in-
creased protection in the non–DR3/DR4-DQ302 protective
group (OR 0.87 for the A allele at rs2290400) with little
association of the allele in the susceptible DR3/DR4-DQ302
group (OR 0.94 for the minor A allele at rs2290400; Table 3).
All other regions had P . 0.007 for statistical interaction
with the DR3/DR4-DQB1*0302 genotype (Supplementary
Table 2).
When SNPs were used to encode DR3/4/X genotypes
rather than as presence or absence of the DR3/DR4-DQ302
genotype (RESEARCH DESIGN AND METHODS), PTPN22-DR3/4/X
deviated from multiplicative interaction on the OR scale
(P = 4.87 3 1024). In addition, there was evidence of
nonmultiplicative statistical interaction on the OR scale
with the cytotoxic T-lymphocyte antigen 4 (CTLA4) SNP,
rs3087243 (P = 7.90 3 1025). The protective rs3087243
T allele conferred greatest protection in those who were
DR4/X and DR3/X, but there was little effect in those with
the DR3/DR3 genotype (Table 4). All other regions had P.
0.006.
DISCUSSION
We report convincing evidence of age-at-diagnosis effects
outside of the HLA region in childhood-onset type 1 di-
abetes. The evidence for genetic effects on age-at-diagnosis
involved SNPs in the IL-2 and RNLS genes. The focus here
was on childhood-onset individuals, but with an emphasis
on adult-onset type 1 diabetes, more loci may yet be
identified. Indeed, a recent study of 1,384 individuals with
autoimmune diabetes aged between 3 and 89 years at di-
agnosis also found suggestive evidence of age-at-diagnosis
TABLE 2
Age-at-diagnosis effects at IL2/4q27 and RNLS/10q23.31








Frequency of the protective
G allele
T/T 8.7 (5.7) 1.00 reference ,5 0.613
G/T 9.0 (6.0) 0.91 [0.84–0.99] 5–8.2 0.625
G/G 9.3 (6.2) 0.80 [0.74–0.88] 8.2–12 0.633
.12 0.641








Frequency of the protective
C allele
T/T 8.9 (5.9) 1.00 reference ,5 0.219
T/C 9.3 (6.1) 0.80 [0.66–0.82] 5–8.2 0.231
C/C 9.5 (6.3) 0.73 [0.66–0.82] 8.2–12 0.242
.12 0.242
The protective alleles for both loci are most common in the older age-groups. ORs with 95% CI were calculated for the protective allele using
the British and Danish cases and controls. Age-at-diagnosis category represents the quartiles of the age-at-diagnosis distribution for cases and
affected offspring.
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effects at IL2 (P = 0.026) and RNLS (P = 0.033) (10). The
same study reported a suggestive association at interleukin
2 receptor a (IL2RA)/10p15.1/ rs2104286 (P = 0.027), a lo-
cus that was close to significant in the present sample set
(P = 9.8 3 1024). Regulator of G-protein signaling 1
(RGS1)/1q31.2, GLIS family zinc finger 3 (GLIS3)/9p24.2,
approached significance in our study, and a further seven
SNPs had P , 0.05 (Supplementary Table 2), but no sup-
port for RGS1 or GLIS3 was obtained previously (10).
The type 1 diabetes risk alleles at all 11 loci with P ,
0.05 for age-at-diagnosis effects were associated with
a younger age-at-diagnosis. The genetic risk score was
strongly correlated with age-at-diagnosis, accounting for
;1% of the variance in age-at-diagnosis (P = 9.2 3 10218).
Stratifying the risk score into quintiles demonstrated
a trend toward an earlier age-at-diagnosis with increasing
risk: average age-at-diagnosis from lowest risk to highest
risk was 8.2, 8.2, 7.8, 7.4, and 7.0 years. Children carrying
a higher dose of the earlier age-at-diagnosis alleles will
probably have an earlier diagnosis of disease compared
with individuals who do not carry these risk alleles, pre-
sumably due to a more rapid development of autoimmu-
nity and/or progression from autoimmunity, as detected by
being autoantibody-positive (10). Another possibility is
that as the immune system matures and ages, alterations in
its functions may nullify the effects of certain susceptibility
alleles, for example, of the genes in the IL-2 pathway, and
so cause these age-at-diagnosis–dependent associations.
The IL-2 pathway is recognized as being important for the
pathogenesis of type 1 diabetes. IL2 SNP genotypes are
correlated with IL-2 gene expression (J. Yang, J.A.T., un-
published data), supporting IL2 as the causal gene in the
chromosome 4q27 region for type 1 diabetes. Two IL-2 re-
ceptor genes, IL2RA and IL2RB, are both associated with
type 1 diabetes susceptibility (1). In the NOD mouse model,
the major non-major histocompatibility complex locus, in-
sulin dependent diabetes susceptibility 3 (Idd3), is the IL2
gene and its effect, via polymorphic gene expression, is
age-dependent (27). The RNLS gene encodes renalase, a
FAD-dependent amine oxidase secreted by the kidney
that circulates in blood and modulates cardiac function
and systemic blood pressure, perhaps through its ability
to metabolize catecholamines (28). Little is known about
its function, if any, in the immune system. Renalase RNA
is expressed in monocytes (http://dil.t1dbase.org/page/
HaemAtlasView). We have found a correlation between the
TABLE 3
Joint effects of HLA class II genotypes, DR3/DR4-DQ302 and rs2476601 at PTPN22 and rs2290400 at GSDMB/ORMDL3






RR [95% CI] for rs2476601 and HLA class II OR [95% CI]
C/C C/T T/T T (rs2476601)
DR3/DR4-DQ302 2,964 (0.36) 3,394 (0.34) 1.00 (reference) 1.70 [1.59–1.81] 2.89 [2.54–3.29] 1.70 [1.59–1.81]
Non-DR3/DR4-DQ302 5,359 (0.64) 6,616 (0.66) 0.10 [0.09–0.11] 0.20 [0.17–0.23] 0.39 [0.30–0.51] 1.98 [1.88–2.09]






RR [95% CI] for rs2290400 and HLA class II OR [95% CI]
G/G G/A A/A A (rs2290400)
DR3/DR4-DQ302 2,995 (0.35) 3,363 (0.34) 1.00 (reference) 0.94 [0.90–0.99] 0.89 [0.81–0.98] 0.94 [0.90–0.99]
Non-DR3/DR4-DQ302 5,451 (0.65) 6,537 (0.66) 0.12 [0.11–0.13] 0.10 [0.09–0.11] 0.09 [0.07–0.11] 0.87 [0.84–0.90]
Interaction was tested for the DR3/DR4-DQ302 genotype vs. the non-DR3/DR4-DQ302 genotype. The SNPs rs2187668 and rs7454108 were used
to tag the HLA-DRB1*03 (DR3) and HLA-DRB1*04 (DR4) class II alleles. For samples with classical genotypes, the DR3/DR4 group was
confined to those who were HLA-DQB1*0302-positive with the protective HLA-DRB1*0403 and *0407 included in the non-DR3/DR4 group.
Effects were estimated in the cases and affected offspring separately and then combined to calculate relative risk (RR) and OR. A small
P value is interpreted as evidence of deviation from multiplicative interaction on the OR scale. Note that cohort effects are accounted for in all
tests. The current study included 2,409 cases analyzed previously by Smyth et al. (20); however, the interaction remained convincing in the
15,923 samples not previously analyzed (P = 1.97 3 1024).
TABLE 4
Joint effects of HLA class II genotypes and rs3087243 at CTLA4






RR [95% CI] for rs3087243 and HLA class II OR [95% CI]
G/G G/A A/A A (rs3087243)
3/4 3,211 (0.37) 3,529 (0.35) 5.73 [5.22–6.28] 4.91 [4.21–5.71] 4.20 [3.00–5.88] 0.86 [0.82–0.90]
3/3 594 (0.07) 798 (0.08) 2.30 [1.98–2.67] 2.21 [1.95–2.52] 2.13 [1.81–2.52] 0.96 [0.88–1.05]
4/4 855 (0.10) 899 (0.09) 2.89 [2.55–3.27] 2.43 [2.17–2.73] 2.05 [1.76–2.40] 0.84 [0.77–0.92]
4/X 2,358 (0.27) 2,686 (0.27) 1.00 (reference) 0.79 [0.75–0.83] 0.62 [0.56–0.69] 0.79 [0.75–0.83]
3/X 1,151 (0.13) 1,433 (0.14) 0.52 [0.47–0.57] 0.42 [0.36–0.48] 0.34 [0.28–0.41] 0.81 [0.76–0.87]
X/X 622 (0.07) 786 (0.08) 0.09 [0.08–0.11] 0.08 [0.07–0.09] 0.07 [0.06–0.08] 0.88 [0.80–0.97]
The HLA genes were coded as DR3/4/X genotypes (3/4, 3/3, 3/X, 4/4, 4/X, X/X) where “X” represents the non-DR3 and non-DR4 alleles, and
included HLA-DRB1*0403 and HLA-DRB1*0407 for samples with classical genotypes available. Effects were estimated in the cases and
affected offspring separately and then combined in order to calculate relative risk (RR) and OR with 95% CI (see RESEARCH DESIGN AND METHODS).
A small P value is interpreted as evidence of deviation from multiplicative interaction. Note that cohort effects are accounted for in all tests.
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type 1 diabetes risk SNPs and SNPs associated with RNA
levels of the RNLS gene in monocytes, implicating it as the
causal gene in the chromosome 10q23.31 region (29).
We tested HLA*non-HLA gene interactions because the
HLA class II genes have the largest effects on type 1 di-
abetes in the genome. Hence, we expect the HLA to have
the highest prior probability of showing a nonmultiplicative
interaction on the OR scale with a non-HLA locus. The
PTPN22-HLA class II genotype interaction is most con-
vincing, probably because the main effect at PTPN22 is
large compared with other non-HLA genes in type 1 diabetes
with a genotype OR $ 3.5. The biological interpretation of
a statistical interaction is difficult, but for PTPN22 and HLA
class II, one can hypothesize that their coexpression and
hence biological interaction in certain cell types critical
for type 1 diabetes, such as T lymphocytes and antigen-
presenting cells, could contribute to our observed statistical
result. The CTLA4*HLA finding requires confirmation in
future studies; however, the result is not surprising given the
key role of HLA class II molecules and CTLA-4 in auto-
antigen presentation and autoreactive T-cell activation.
Further insights into these molecules and their role in dis-
ease require detailed laboratory-based investigations.
Our findings here illustrate that statistical gene–gene
interactions can be detected, and we can anticipate that
evidence for many more interactions may be found (and
those we report confirmed) with larger numbers of sam-
ples, and with the use of non-European samples. However,
in keeping with another report (4), our data suggest that
for common variants with ORs , 2, statistical interactions
are unlikely to contribute substantially to the “missing
heritability” in type 1 diabetes.
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